Abstract:Polycystic liver disease (PLD) is a rare condition observed in three genetic diseases, including autosomal dominant polycystic liver disease (ADPLD), autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD). PLD usually does not impair liver function, and advanced PLD becomes symptomatic when the enlarged liver compresses adjacent organs or increases intra-abdominal pressure. Currently, the diagnosis of PLD is mainly based on imaging, and genetic testing is not required except for complex cases. Besides, genetic testing may help predict patients' prognosis, classify patients for genetic intervention, and conduct early treatment. Although the underlying genetic causes and mechanisms are not fully understood, previous studies refer to primary ciliopathy or impaired ciliogenesis as the main culprit. Primarily, PLD occurs due to defective ciliogenesis and ineffective endoplasmic reticulum quality control. Specifically, loss of function mutations of genes that are directly involved in ciliogenesis, such as Pkd1 , Pkd2, Pkhd1, and Dzip1l, can lead to both hepatic and renal cystogenesis in ADPKD and ARPKD. In addition, loss of function mutations of genes that are involved in endoplasmic reticulum quality control and protein folding, trafficking, and maturation, such as PRKCSH , Sec63, ALG8 , ALG9 , GANAB , and SEC61B, can impair the production and function of polycystin1 (PC1) and polycystin 2 (PC2) or facilitate their degradation and indirectly promote isolated hepatic cystogenesis or concurrent hepatic and renal cystogenesis. Recently, it was shown that mutations of LRP5, which impairs canonical Wnt signaling, can lead to hepatic cystogenesis. PLD is currently treated by somatostatin analogs, percutaneous intervention, surgical fenestration, resection, and liver transplantation. In addition, based on the underlying molecular mechanisms and signaling pathways, several investigational treatments have been used in preclinical studies, some of which have shown promising results. This review discusses the clinical manifestation, complications, prevalence, genetic basis, and treatment of PLD and explains the investigational methods of treatment and future research direction, which can be beneficial for researchers and clinicians interested in PLD.

Genetics and mechanisms of hepatic cystogenesis

Liver cyst gene knockout in cholangiocytes inhibits cilium formation and Wnt signaling

Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease

Isolated polycystic liver disease genes define effectors of polycystin-1 function

[Mechanisms of polycystic kidney diseases inducing male reproductive disorders].

Autosomal Dominant Polycystic Kidney Disease with Ectopic Unilateral Multicystic Dysplastic Kidney

A <i>BBS4</i> mutation causes autosomal dominant polycystic liver disease

A SEC61A1 variant is associated with autosomal dominant polycystic liver disease

The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease-A Primer for Clinicians

Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management

The Role of the Co-Chaperone DNAJB11 in Polycystic Kidney Disease: Molecular Mechanisms and Cellular Origin of Cyst Formation

Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease

Novel GANAB variants associated with polycystic liver disease

Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease

Polycystic Kidney Disease: Novel Insights into Polycystin Function.

Overexpression of Aquaporin 1 on Cysts of Patients with Polycystic Liver Disease.

Factors Associated With the Development and Severity of Polycystic Liver in Patients With Autosomal Dominant Polycystic Kidney Disease

Fatal liver cyst rupture in polycystic liver disease complicated with autosomal dominant polycystic kidney disease: A case report.

EZH2 inhibition or genetic ablation suppresses cyst growth in autosomal dominant polycystic kidney disease

Somatic Mutations in Renal Cyst Epithelium in Autosomal Dominant Polycystic Kidney Disease.

A Rare Deep Intronic Mutation of PKHD1 Gene, C.8798-459 C > A, Causes Autosomal Recessive Polycystic Kidney Disease by Pseudoexon Activation